awmsg logo



plerixafor (Mozobil®)


Reference No. 249

Publication date:
08/04/2010


Appraisal information

plerixafor (Mozobil®) 20 mg/ml solution for injection


Company: Genzyme Therapeutics
BNF category: Nutrition and blood
NMG meeting date: 20/01/2010
AWMSG meeting date: 03/03/2010
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0110
Ministerial ratification: 31/03/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Plerixafor (Mozobil®) is recommended as an option for restricted use within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. Plerixafor (Mozobil®) should be restricted for use specifically in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) who have already failed one complete mobilisation attempt. AWMSG is of the opinion that plerixafor (Mozobil®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download